RecentRCT

MINT prespecified exacerbation and rescue analysis

Primary publication linked by DOI, 2026 · Prespecified analysis of an international double-blind phase 3 RCT

Population: 238 AChR-positive or MuSK-positive adults with generalized MG
Intervention: Inebilizumab with protocol steroid taper
Comparator: Placebo with protocol steroid taper
Primary outcome: Exacerbation including rescue treatment
Result: Combined population week-26 exacerbation HR 0.41 (95% CI 0.24–0.70).

What the trial found

Combined population week-26 exacerbation HR 0.41 (95% CI 0.24–0.70).

Clinical interpretation

Prespecified secondary analysis supports prevention during longer-term treatment; it is not an acute-crisis rescue trial.

Moderate certainty

Clinical Context & Relevant Topics (1)

Disease Reference

Myasthenia Gravis & Myasthenic Crisis

Dedicated ICU management of myasthenic crisis: respiratory mechanics, airway timing, IVIG/plasma exchange, trigger control, medication hazards, and extubation.

View Topic Context →